Article
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Clinical lung cancer - 1 Nov 2023
Wolf Jürgen, Souquet Pierre-Jean, Goto Koichi, Cortot Alexis, Baik Christina, Heist Rebecca, Kim Tae Min, Han Ji-Youn, Neal Joel W, Mansfield Aaron S, Gilloteau Isabelle, Nwana Ngozi, Waldron-Lynch Maeve, Davis Keith L, Giovannini Monica, Awad Mark M
Abstract excerpt
BACKGROUND: We evaluated the disease and patient characteristics, treatment, and MET testing patterns, predictive biomarkers and survival outcomes in patients with MET-dysregulated metastatic non-small-cell lung cancer (NSCLC) in a real-world setting. PATIENTS AND METHODS: This was a multinational, retrospective, noninterventional chart review study. Data from medical records of patients with advanced/metastatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.